Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 121Paclitaxel 105Gemcitabine 91Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Dexamethasone 62Cyclophosphamide 60Pemetrexed 58Capecitabine 56Bevacizumab 56durvalumab 54Oxaliplatin 51Radiotherapy 50Doxorubicin 50Fluorouracil 49Radiation 46Leucovorin 44Rituximab 43Lenalidomide 42Vincristine 40Etoposide 38Nivolumab 37atezolizumab 36Letrozole 35130-nm albumin-bound paclitaxel 33Irinotecan 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × epacadostat × 90 days × Clear all
NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡